|
1. Ando S. Neuronal dysfunction with aging and its amelioration. Proc Jpn Acad Ser B Phys Biol Sci. 2012. 88(6):266-82. 2. Turner RJ, Sharp FR. Implications of MMP9 for blood–brain barrier disruption and hemorrhagic transformation following ischemic stroke. Front Cell Neurosci. 2016. 4;10:56. 3. Alluri H, Wiggins-Dohlvik K, Davis ML, Huang JH, Tharakan B. Blood-brain barrier dysfunction following traumatic brain injury. Metab Brain Dis. 2015. 30(5):1093-104. 4. Querfurth HW, LaFerla FM. Alzheimer's disease. N Engl J Med. 2010. 28;362(4):329-44. 5. Sveinbjornsdottir S. The clinical symptoms of Parkinson's disease. J Neurochem. 2016. 139 Suppl 1:318-324. 6. Ha AD, Fung VS. Huntington's disease. Curr Opin Neurol. 2012. 25(4):491-8. 7. Tiryaki E, Horak HA. ALS and other motor neuron diseases. Continuum (Minneap Minn). 2014. 20(5 Peripheral Nervous System Disorders):1185-207. 8. Eric A. Huebner and Stephen M. Strittmatter. Axon Regeneration in the Peripheral and Central Nervous Systems. Results Probl Cell Differ. 2009. 48: 339–351. 9. Raivich G, Bohatschek M, et al. The AP-1 transcription factor c-Jun is required for efficient axonal regeneration. Neuron. 2004. 8; 43(1):57-67. 10. Seijffers R, Allchorne AJ, Woolf CJ. The transcription factor ATF-3 promotes neurite outgrowth. Mol Cell Neurosci. 2006. 32(1-2):143-54. 11. Bonilla IE, Tanabe K, Strittmatter SM. Small proline-rich repeat protein 1A is expressed by axotomized neurons and promotes axonal outgrowth. J Neurosci. 2002. 15; 22(4):1303-15. 12. Bomze HM, Bulsara KR, et al. Spinal axon regeneration evoked by replacing two growth cone proteins in adult neurons. Nat Neurosci. 2001. 4(1):38-43. 13. Chen MS, Huber AB, et al. Nogo-A is a myelin-associated neurite outgrowth inhibitor and an antigen for monoclonal antibody IN-1. Nature. 2000 Jan 27; 403(6768):434-9. 14. GrandPré T, Nakamura F, et al. Identification of the Nogo inhibitor of axon regeneration as a Reticulon protein. Nature. 2000 Jan 27; 403(6768):439-44. 15. McKerracher L, David S, et al. Identification of myelin-associated glycoprotein as a major myelin-derived inhibitor of neurite growth. Neuron. 1994 Oct; 13(4):805-11. 16. Kottis V, Thibault P, et al. Oligodendrocyte-myelin glycoprotein (OMgp) is an inhibitor of neurite outgrowth. J Neurochem. 2002 Sep; 82(6):1566-9. 17. Benson MD, Romero MI, et al. Ephrin-B3 is a myelin-based inhibitor of neurite outgrowth. Proc Natl Acad Sci U S A. 2005 Jul 26; 102(30):10694-9. 18. Moreau-Fauvarque C, Kumanogoh A, et al. The transmembrane semaphorin Sema4D/CD100, an inhibitor of axonal growth, is expressed on oligodendrocytes and upregulated after CNS lesion. J Neurosci. 2003 Oct 8; 23(27):9229-39. 19. Atwal JK, Pinkston-Gosse J, et al. PirB is a functional receptor for myelin inhibitors of axonal regeneration. Science. 2008 Nov 7; 322(5903):967-70. 20. Chen B, Hammonds-Odie L, et al. SHP-2 mediates target-regulated axonal termination and NGF-dependent neurite growth in sympathetic neurons. Dev Biol. 2002 Dec 15;252(2):170-87. 21. Geoffroy CG, Zheng B. Myelin-associated inhibitors in axonal growth after CNS injury. Curr Opin Neurobiol. 2014 Aug; 27:31-8. doi: 10.1016. 22. Asher RA, Morgenstern DA, et al. Neurocan is upregulated in injured brain and in cytokine-treated astrocytes. J Neurosci. 2000 Apr 1; 20(7):2427-38. 23. Schmalfeldt M, Bandtlow CE, et al. Brain derived versican V2 is a potent inhibitor of axonal growth. J Cell Sci. 2000 Mar; 113 (Pt 5):807-16. 24. Yamada H, Fredette B, et al. The brain chondroitin sulfate proteoglycan brevican associates with astrocytes ensheathing cerebellar glomeruli and inhibits neurite outgrowth from granule neurons. J Neurosci. 1997 Oct 15; 17(20):7784-95. 25. Inatani M, Honjo M, et al. Inhibitory effects of neurocan and phosphacan on neurite outgrowth from retinal ganglion cells in culture. Invest Ophthalmol Vis Sci. 2001 Jul; 42(8):1930-8. 26. Dou CL, Levine JM. Inhibition of neurite growth by the NG2 chondroitin sulfate proteoglycan. J Neurosci. 1994 Dec; 14(12):7616-28. 27. Rhodes K E, Fawcett J W. Chondroitin sulphate proteoglycans: Preventing plasticity or protecting the CNS? Journal of Anatomy. 2004. 204 (1): 33–48. doi:10.1111. 28. Justin R Siebert, Donna J Osterhout. The inhibitory effects of chondroitin sulfate proteoglycans on oligodendrocytes. J Neurochem. 2011. 119, 176–188. 29. Jones L L, Margolis R U, Tuszynski M H. The chondroitin sulfate proteoglycans neurocan, brevican, phosphacan, and versican are differentially regulated following spinal cord injury. 2003. Experimental Neurology. 182 (2): 399–411. 30. Stichel C C, Muller H W. Experimental strategies to promote axonal regeneration after traumatic central nervous system injury. Neurobiol. 1998. 56:119-148 31. Goldberg JL, Klassen MP, et al. Amacrine-signaled loss of intrinsic axon growth ability by retinal ganglion cells. Science. 2002. 7;296(5574):1860-4. 32. Philip J Horner, Fred H Gage. Regenerating the damaged central nervous system. Nature. 2000.407,963-970. 33. Blackmore M, Letourneau PC, et al. Changes within maturing neurons limit axonal regeneration in the developing spinal cord. J Neurobiol. 2006. 66(4):348-60. 34. Yiu G, He Z, et al. Glial inhibition of CNS axon regeneration. Nat Rev Neurosci. 2006 Aug;7(8):617-27. 35. Harel NY, Strittmatter SM, et al. Can regenerating axons recapitulate developmental guidance during recovery from spinal cord injury? Nat Rev Neurosci. 2006 Aug;7(8):603-16. 36. Waddington CH. The epigenotype. Endeavour. 1942; 1:18–20. 37. Wu Ct, Morris JR. Genes, genetics, and epigenetics: a correspondence. Science. 2001 Aug 10; 293(5532):1103-5. 38. Li E, Beard C, Jaenisch R. Role for DNA methylation in genomic imprinting. Nature. 1993. 366 (6453): 362–65. 39. Mattick JS, Amaral PP, et al. RNA regulation of epigenetic processes. BioEssays. 2009. 31 (1): 51–59. 40. Kouzarides T. Chromatin modifications and their function. Cell. 2007. 23; 128(4):693-705. 41. Cathérine Dupont, D Randall Armant, Carol A Brenner. Epigenetics: Definition, Mechanisms and Clinical Perspective. Semin Reprod Med. 2009. 27(5): 351–357. 42. Yang XJ, Seto E. HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention. Oncogene. 2007 Aug 13;26(37):5310-8. 43. Lee KK, Workman JL. Histone acetyltransferase complexes: one size doesn't fit all. Nature Reviews. Molecular Cell Biology. 2007. 8 (4): 284–95. doi:10.1038 44. Loredana Verdone, et al. Histone acetylation in gene regulation. Briefings in Functional Genomics and Proteomics. 2006. 5 (3):209-221. 45. Wang Z, Zang C, et al. Genome-wide mapping of HATs and HDACs reveals distinct functions in active and inactive genes. Cell. 2009. 138: 1019-31. 46. Hsieh J, Nakashima K, et al. Histone deacetylase inhibition-mediated neuronal differentiation of multipotent adult neural progenitor cells. Proc Natl Acad Sci USA. 2004. 101: 16659-64. 47. Crosio C, Heitz E, et al. Chromatin remodeling and neuronal response: multiple signaling pathways induce specific histone H3 modifications and early gene expression in hippocampal neurons. J Cell Sci. 2003. 116: 4905-14. 48. Roth TL, Sweatt JD. Regulation of chromatin structure in memory formation. Curr Opin Neurobiol. 2009. 19: 336-42. 49. Barrett RM, Wood MA. Beyond transcription factors: the role of chromatin modifying enzymes in regulating transcription required for memory. Learn Mem. 2008. 15: 460 50. Lucia Peixoto, Ted Abel. The Role of Histone Acetylation in Memory Formation and Cognitive Impairments. Neuropsychopharmacology. 2013 Jan; 38(1): 62–76. 51. Kim AH, Puram SV, et al. A centrosomal Cdc20-APC pathway controls dendrite morphogenesis in postmitotic neurons. Cell. 2009 Jan 23; 136(2):322-36. 52. Yongcheol Cho, Roman Sloutsky, et al. Injury-induced HDAC5 nuclear export is essential for axon regeneration. Cell. 2013. 155(4): 894–908 53. Puttagunta R, et al. PCAF-dependent epigenetic changes promote axonal regeneration in the central nervous system. Nature Communications. 2014. doi:10.1038 /ncomms4527 54. Vanhaecke T, Papeleu P, Elaut G, Rogiers V. Trichostatin A-like hydroxamate histone deacetylase inhibitors as therapeutic agents: toxicological point of view. Curr Med Chem. 2004. 11 (12): 1629–43. 55. Drummond DC, Noble CO, et al. Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol. 2005. 45:495-528. 56. Gaub P, Tedeschi A, et al. HDAC inhibition promotes neuronal outgrowth and counteracts growth cone collapse through CBP/P300 and P/CAF-dependent p53 acetylation. Cell Death Differ. 2010. 17(9):1392-408. 57. Tan J, Jiang X, et al. Anacardic acid induces cell apoptosis of prostatic cancer through autophagy by ER stress/DAPK3/Akt signaling pathway. Oncol Rep. 2017 Sep;38(3):1373-1382. 58. Shen Lin,a Kutaiba Nazif, et al. Histone acetylation inhibitors promote axon growth in adult DRG neurons. J Neurosci Res. 2015. 93(8): 1215–1228. 59. Yongcheol Cho, Valeria Cavalli, et al. HDAC signaling in neuronal development and axon regeneration. Curr Opin Neurobiol. 2014. 0: 118–126. 60. Tropberger P, Pott S, et al. Regulation of transcription through acetylation of H3K122 on the lateral surface of the histone octamer. Cell. 2013.152:859-872. 61. Delvecchio M, Gaucher J, et al. Structure of the P300 catalytic core and implications for chromatin targeting and HAT regulation. Nat. Struct. Mol. Biol. 2013. 20:1040-1046. 62. Ogryzko V V, Schiltz R L, et al. The transcriptional coactivators P300 and CBP are histone acetyltransferases. Cell. 1996.87:953-959. 63. Iioka T, Furukawa K, et al. P300/CBP acts as a coactivator to cartilage homeoprotein-1 (Cart1), paired-like homeoprotein, through acetylation of the conserved lysine residue adjacent to the homeodomain. J. Bone Miner. Res. 2003. 18:1419-1429. 64. Qiu Y, Zhao Y, et al. HDAC1 acetylation is linked to progressive modulation of steroid receptor-induced gene transcription. Mol. Cell. 2006. 22:669-679. 65. Han Y, Jin Y H, et al. Acetylation of Sirt2 by P300 attenuates its deacetylase activity. Biochem. Biophys. Res. Commun. 2008. 375:576-580. 66. Braganca J, Eloranta J J, et al. Physical and functional interactions among AP-2 transcription factors, P300/CREB-binding protein, and CITED2. J. Biol. Chem. 2003. 278:16021-16029. 67. Curtis A M, Seo S B, et al. Histone acetyltransferase-dependent chromatin remodeling and the vascular clock. J. Biol. Chem. 2004. 279:7091-7097. 68. Sabari B R, Tang Z, et al. Intracellular crotonyl-CoA stimulates transcription through P300-catalyzed histone crotonylation. Mol. Cell. 2015. 58:203-215. 69. Chen Y, Sprung R, et al. Lysine propionylation and butyrylation are novel post-translational modifications in histones. Mol. Cell. Proteomics. 2007. 6:812-819. 70. Marosi K, Kim S W, et al. 3-Hydroxybutyrate regulates energy metabolism and induces BDNF expression in cerebral cortical neurons. J Neurochem. 2016 Dec;139(5):769-781. 71. Sanders YY, Liu H, Zhang X, et al. Histone modifications in senescence-associated resistance to apoptosis by oxidative stress. Redox Biol 2013; 1: 8–16. 72. Shu XZ, Zhang LN, et al. Histone acetyltransferase P300 promotes MRTF-A-mediates transactivation of VE-cadherin gene in human umbilical vein endothelial cells. Gene 2015; 563: 17–23. 73. Li N, Yuan Q, et al. Opposite effects of HDAC5 and P300 on MRTF-A-related neuronal apoptosis during ischemia/reperfusion injury in rats. Cell Death Dis. 2017 Feb 23;8(2):e2624. 74. Gaub P, Joshi Y, et al. The histone acetyltransferase P300 promotes intrinsic axonal regeneration. Brain. 2011 Jul;134(Pt 7):2134-48. 75. Tomioka T, Maruoka H, et al. The histone deacetylase inhibitor trichostatin A induces neurite outgrowth in PC12 cells via the epigenetically regulated expression of the nur77 gene. Neurosci Res. 2014. 88:39-48. doi: 10.1016. 76. Amit K Patel, Kevin K Park, et al. Wnt signaling promotes axonal regeneration following optic nerve injury in the mouse. Neuroscience. 2017 Feb 20; 343: 372–383. 77. Hemshekhar M, et al. Emerging roles of anacardic acid and its derivatives: a pharmacological overview. Basic Clin Pharmacol Toxicol. 2012 Feb;110(2):122-32. 78. Sun Y, et al. Inhibition of histone acetyltransferase activity by anacardic acid sensitizes tumor cells to ionizing radiation. FEBS Lett. 2006;580:4353–6. 79. Schneider A,et al. Acetyltransferases (HATs) as targets for neurological therapeutics. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics. 2013; 10(4):568–588. 80. Valor LM, et al. Lysine acetyltransferases CBP and P300 as therapeutic targets in cognitive and neurodegenerative disorders. Current pharmaceutical design. 2013; 19(28):5051–5064. 81. Creppe C, Buschbeck M. Elongator: an ancestral complex driving transcription and migration through protein acetylation. Journal of biomedicine & biotechnology. 2011; 2011:924898. 82. Akella JS, et al. MEC-17 is an alpha-tubulin acetyltransferase. Nature. 2010; 467(7312):218–222. 83. Kalebic N, et al. alphaTAT1 is the major alpha-tubulin acetyltransferase in mice. Nature communications. 2013; 4:1962. 84. Song Y, Brady ST. Post-translational modifications of tubulin: pathways to functional diversity of microtubules. Trends Cell Biol. 2015 Mar;25(3):125-36.
|